Capital Fund Management (CFM)
ABCL icon

Capital Fund Management (CFM)’s AbCellera Biologics ABCL Stock Holding History

Capital Fund Management (CFM)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55,452
Closed -$418K – 1646
2023
Q1 		$418K Sell
55,452
-130,516
-70% -$1.19M ﹤0.01% 1462
2022
Q4 		$1.88M Buy
185,968
+155,691
+514% +$1.8M 0.01% 960
2022
Q3 		$299K Buy
+30,277
New +$332K ﹤0.01% 1353

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital Fund Management (CFM)'s ABCL Position: Q2 2023 in Review

Capital Fund Management (CFM) sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 55,452 shares — an estimated $418K sold.

Capital Fund Management (CFM) first reported a position in ABCL in Q3 2022 and held it in 3 quarters. The position peaked at $1.88M in Q4 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Capital Fund Management (CFM) reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 55,452 AbCellera Biologics shares in Q2 2023, an estimated $418K.
  • Capital Fund Management (CFM) first reported a position in AbCellera Biologics in Q3 2022 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s AbCellera Biologics position peaked at $1.88M in Q4 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2023, filed 14 Aug 2023.